Skip to main content
. 2024 Mar 4;16:1329551. doi: 10.3389/fnagi.2024.1329551

TABLE 3.

Olfaction and time interaction effects on clinical assessment trajectories: GEE analysis.

Crude model Adjusted model
Olfaction Olfaction × Time Olfaction Olfaction × Time
Crude Crude Adjusted Adjusted
B p B p B p B P
Age 0.2 0.950 0.1 0.191
Duration 28.7 0.035* −0.4 0.644
LEDD 326.4 0.006* −16.5 0.785
UPSIT −10.3 <0.001* 0.8 0.239 −10.0 <0.001* 0.9 0.176
MOCA 0.6 0.651 −1.8 0.013* 1.3 0.297 −1.8 0.012*
M-UPDRS
Total 15.3 0.056 −1.5 0.659 10.9 0.179 −1.9 0.602
Part III 7.9 0.080 −1.0 0.603 7.7 0.080 −1.3 0.517
PDQ-39
SI 1.9 0.735 0.0 0.998 −2.0 0.707 0.0 0.985
ADL 3.7 0.615 0.9 0.771 −2.4 0.755 1.2 0.722
COG 6.5 0.405 −2.1 0.579 1.1 0.887 −2.3 0.565

The olfaction effects were compared between anosmia and non-anosmia groups. Adjustments were made for age, sex, disease duration, and LEDD. Data indicates a faster cognitive decline in the anosmia group (olfaction × time effect on MoCA scores adjusted B = −1.8, p = 0.012). Anosmia: baseline UPSIT < 19; Non-anosmia: baseline UPSIT ≥ 19. ADL, activities of daily living; B, beta coefficient; COG, cognitions; GEE, generalized estimating equation; LEDD, levodopa equivalent daily dose; MoCA, Montreal cognitive assessment; M-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PDQ-39, Chinese-translated version of 39-item Parkinson’s Disease Questionnaire; SI, summary index; UPSIT, traditional Chinese version of the University of Pennsylvania Smell Identification Test.

*p < 0.05.